AI Article Synopsis
- Urate oxidase (Uox)-deficient mice are a promising model to study hyperuricemia and related disorders, developed using the Cre/loxP gene targeting system.
- These Uox mice naturally develop high levels of serum urate and show increased de novo purine biosynthesis in the liver, indicating a link between elevated urate levels and purine synthesis.
- Treatments like pegloticase and allopurinol can effectively lower serum urate and inhibit related enzyme increases, while the majority of Uox mice maintain a normal lifespan despite some developing urate nephropathy by 30 weeks of age.
Article Abstract
Urate oxidase (Uox)-deficient mice could be an optimal animal model to study hyperuricemia and associated disorders. We develop a liver-specific conditional knockout Uox-deficient (Uox) mouse using the Cre/loxP gene targeting system. These Uox mice spontaneously developed hyperuricemia with accumulated serum urate metabolites. Blocking urate degradation, the Uox mice showed significant de novo purine biosynthesis (DNPB) in the liver along with amidophosphoribosyltransferase (Ppat). Pegloticase and allopurinol reversed the elevated serum urate (SU) levels in Uox mice and suppressed the Ppat up-regulation. Although urate nephropathy occurred in 30-week-old Uox mice, 90 % of Uox-deficient mice had a normal lifespan without pronounced urate transport abnormality. Thus, Uox mice are a stable model of human hyperuricemia. Activated DNPB in the Uox mice provides new insights into hyperuricemia, suggesting increased SU influences purine synthesis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbadis.2023.167009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!